NASDAQ$AMGN

Amgen Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Announced financial results, demonstrating revenue growth driven by increased unit demand and solid performance of key products.

Amgen reported a 4% increase in total revenues to $6.7 billion for the third quarter of 2021, driven by higher unit demand. GAAP EPS decreased 3% to $3.31, while non-GAAP EPS increased 11% to $4.67. The company generated $2.2 billion in free cash flow.

  • Total revenues increased 4% to $6.7 billion, driven by higher unit demand.
  • GAAP EPS decreased 3% to $3.31, impacted by a licensing-related expense.
  • Non-GAAP EPS increased 11% to $4.67, driven by increased revenues.
  • Generated $2.2 billion of free cash flow, influenced by COVID-19 related payment terms in the prior year.

Headline financials

Total Revenue

$6.71B

Previous: $6.42B+4.4%
EPS (adj)

$4.67

Previous: $4.37+6.9%
Capital Expenditures

-$593M

Previous: -$435M-36.3%
Free Cash Flow

$1.29B

Previous: $1.59B-18.6%
Net Income

$1.88B

Previous: $2.02B-6.8%
Operating Income

$2.38B

Previous: $2.45B-3.1%
Gross Profit

$5.1B

Previous: $4.86B+4.8%
Cash & Equivalents

$12B

Previous: $9.09B+31.7%
Total Assets

$65B

Previous: $64.6B+0.6%

Revenue & EPS history

Amgen · Revenue · Quarterly

$6.71B

Q3 2021+4.4%vs Q3 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Amgen · $5.33B total across 14 segments · Q3 2021

  • Enbrel
    $1.29B-2.7%
  • Prolia
    $803M+14.6%
  • Otezla
    $609M+13.2%
  • XGEVA
    $517M+7.5%
  • Aranesp
    $396M+3.1%
  • KYPROLIS
    $293M+12.7%
  • MVASI
    $274M+18.6%
  • Nplate
    $273M+28.8%
  • Repatha
    $272M+32.7%
  • Vectibix
    $200M+3.6%
  • EVENITY
    $149M+152.5%
  • BLINCYTO
    $125M+40.4%
  • Other products
    $93M+12.0%
  • LUMAKRAS/LUMYKRAS
    $36M

Forward guidance

Amgen provided full year 2021 guidance, expecting total revenues in the range of $25.8 billion to $26.2 billion, GAAP EPS in the range of $9.55 to $10.21, and non-GAAP EPS in the range of $16.50 to $17.10.

Tailwinds

  • Total revenues in the range of $25.8 billion to $26.2 billion.
  • GAAP EPS in the range of $9.55 to $10.21.
  • Non-GAAP EPS in the range of $16.50 to $17.10.
  • Capital expenditures to be approximately $900 million.
  • Share repurchases at the upper end of $3.0 billion to $5.0 billion range.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+0.3%

Avg return

Earnings day

+0.0%

Avg return

5 days after

+0.1%

Avg return

30 days after

53%

39 / 73 earnings

Positive

+12.2%

Q1 2024

Best reaction

-8.7%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.9%-4.4%-2.7%
Q4 2025+3.0%+11.0%+9.1%
Q3 2025+7.7%+9.1%+11.2%
Q2 2025-5.1%-5.0%-5.5%
Q1 2025-1.1%-2.8%+1.6%
Q4 2024+6.5%+2.0%+12.4%
Q3 2024+1.3%+0.3%-10.5%
Q2 2024-3.9%-0.8%-0.3%
Q1 2024+12.2%+8.3%+10.3%
Q4 2023-8.1%-9.6%-15.3%
Q3 2023-0.9%+2.5%+2.5%
Q2 2023+5.6%+13.2%+11.4%
Q1 2023+0.4%-1.2%-9.2%
Q4 2022-2.1%-2.6%-6.7%
Q3 2022+0.0%+8.7%+6.1%
Q2 2022-0.4%+0.5%-1.9%
Q1 2022-4.7%-7.6%+2.2%
Q4 2021+8.5%+2.7%+4.2%
Q3 2021+4.0%+1.9%-4.1%
Q2 2021-4.8%-4.0%-5.8%
Q1 2021-7.4%-6.2%-7.9%
Q4 2020-1.4%-1.7%-7.7%
Q3 2020-2.5%-1.5%+0.6%
Q2 2020-1.9%-3.5%-0.3%
Q1 2020-2.0%+0.3%-2.5%
Q4 2019-4.9%-2.4%-12.1%
Q3 2019+2.9%+6.3%+14.4%
Q2 2019+6.0%+6.3%+17.5%
Q1 2019-2.8%-2.1%-6.7%
Q4 2018-3.7%-2.5%-1.0%
Q3 2018+2.4%-0.6%+7.5%
Q2 2018-0.3%+1.8%+1.9%
Q1 2018+0.1%+1.6%+1.9%
Q4 2017+0.5%-5.1%-0.5%
Q3 2017-2.1%-3.2%-5.7%
Q2 2017-2.9%-3.6%-6.1%
Q1 2017-1.2%-1.3%-5.9%
Q4 2016+4.9%+4.5%+12.9%
Q3 2016-8.7%-11.5%-8.5%
Q2 2016+2.2%+3.9%+2.6%
Q1 2016-1.7%
Q4 2015+1.5%
Q3 2015-0.9%
Q2 2015+3.0%
Q1 2015+1.9%
Q4 2014-3.2%
Q3 2014+6.7%
Q2 2014+6.0%
Q1 2014-3.2%
Q4 2013+0.5%
Q3 2013+1.8%
Q2 2013-1.0%
Q1 2013-7.5%
Q4 2012-0.8%
Q3 2012+0.8%
Q2 2012+7.6%
Q1 2012+0.2%
Q4 2011-0.8%
Q3 2011+4.9%
Q2 2011-3.0%
Q1 2011-1.5%
Q4 2007+0.7%
Q4 2010+0.7%
Q3 2008+0.7%
Q3 2010-0.9%
Q2 2010-0.4%
Q1 2009+1.5%
Q1 2010+1.2%
Q4 2009+0.5%
Q3 2009+1.6%
Q4 2008+3.8%
Q2 2009+3.8%
Q2 2008+3.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro